VTGN News and Press, VistaGen Therapeutics Inc. From 05/14/21

Shares of VistaGen Therapeutics (VTGN) are down 1.4% in after-hours trading after announcing it had filed for a $75M at-the-market offering.Jefferies will act as sales agent.VistaGen shares closed down 18.7% for the week but are up 9.8% year-to-date. For furthe...

VistaGen (NASDAQ: VTGN) , a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Ann Cunningham ...

VistaGen (VTGN) has named Ann Cunningham as its news chief commercial officer.She has been serving on the company's board since January 2019.Prior to her new role, her most recent positions included managing partner of i3 Strategy Partners and VP, neurodegenerative disease and psychiatry...

SOUTH SAN FRANCISCO, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and othe...

3 Penny Stocks Making Big Waves in the Biotech Industry Penny stocks have remained some of the most popular assets over the past year or so. While this began as a way to capitalize on penny stocks benefitting from the pandemic, investors are now finding biotech stocks simply bec...

3 Things Every Penny Stock Trader Needs to Know in 2021 Investing in penny stocks in 2021 can be difficult if you don’t have the right information on hand. And while looking at penny stock watchlists can help with inspiration, the best way to be confident in your strategy is ...

VistaGen (NASDAQ: VTGN) , a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Joanne Curley, ...

SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and...

VistaGen has a potentially pivotal Phase 3 trial of its Social Anxiety Disorder ("SAD") treatment PH94B upcoming. The trial is near-identical to its successful Phase 2 trial. The neurology specialist has 2 other candidates in development - 1 acquired from the same team that developed ...

VistaGen has had a tumultuous history, but recent trials have seen success. They may start phase 3 trials for PH94B in May. Dilution is a major risk. For further details see: VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin